170 related articles for article (PubMed ID: 32116188)
1. TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis.
Zhang P; Zhou S; Chen Z; Tian Y; Wang Q; Li H; Zhang T; Guo Q; Wang M; Guo C
Curr Pharm Biotechnol; 2021; 22(2):305-316. PubMed ID: 32116188
[TBL] [Abstract][Full Text] [Related]
2. [The function of bushen qiangdu recipe containing serum in OPG/RANKL pathway of ankylosing spondylitis patients].
Xu Y; Ya XP; Zhang WJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):521-4. PubMed ID: 22803436
[TBL] [Abstract][Full Text] [Related]
3. CXCL16/CXCR6 is involved in LPS-induced acute lung injury via P38 signalling.
Tu GW; Ju MJ; Zheng YJ; Hao GW; Ma GG; Hou JY; Zhang XP; Luo Z; Lu LM
J Cell Mol Med; 2019 Aug; 23(8):5380-5389. PubMed ID: 31199046
[TBL] [Abstract][Full Text] [Related]
4. RANKL downregulates cell surface CXCR6 expression through JAK2/STAT3 signaling pathway during osteoclastogenesis.
Li C; Zhao J; Sun L; Yao Z; Liu R; Huang J; Liu X
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):156-62. PubMed ID: 23142594
[TBL] [Abstract][Full Text] [Related]
5. CXCL16/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K/AKT/FOXO3a pathway.
Ma Z; Yu R; Zhu Q; Sun L; Jian L; Wang X; Zhao J; Li C; Liu X
Int Immunopharmacol; 2020 Apr; 81():106035. PubMed ID: 31753588
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.
Fang Y; Li LJ; Wang R; Huang F; Song HF; Tang ZM; Li YZ; Guan HS; Zheng QS
Acta Pharmacol Sin; 2010 Nov; 31(11):1500-7. PubMed ID: 20953211
[TBL] [Abstract][Full Text] [Related]
7. CXCL16/CXCR6 interaction promotes endometrial decidualization via the PI3K/AKT pathway.
Mei J; Yan Y; Li SY; Zhou WJ; Zhang Q; Li MQ; Sun HX
Reproduction; 2019 Mar; 157(3):273-282. PubMed ID: 30620718
[TBL] [Abstract][Full Text] [Related]
8. [Expression of CXCL16/CXCR6 in fibroblast-like synoviocytes in rheumatoid arthritis and its role in synoviocyte proliferation].
Zhang X; Zhao JX; Sun L; Liu XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):663-668. PubMed ID: 28816285
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
10. Activation of the CXCL16/CXCR6 Axis by TNF-α Contributes to Ectopic Endometrial Stromal Cells Migration and Invasion.
Peng Y; Ma J; Lin J
Reprod Sci; 2019 Mar; 26(3):420-427. PubMed ID: 29779473
[TBL] [Abstract][Full Text] [Related]
11. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.
Jin Q; Cirelli JA; Park CH; Sugai JV; Taba M; Kostenuik PJ; Giannobile WV
J Periodontol; 2007 Jul; 78(7):1300-8. PubMed ID: 17608585
[TBL] [Abstract][Full Text] [Related]
12. CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway.
Li CH; Xu LL; Zhao JX; Sun L; Yao ZQ; Deng XL; Liu R; Yang L; Xing R; Liu XY
Inflamm Res; 2016 Mar; 65(3):193-202. PubMed ID: 26621504
[TBL] [Abstract][Full Text] [Related]
13. [Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases].
Aguilar Del Rey FJ; García Portales R; Haro Liger M; Rodríguez Andreu J; Casals Sánchez JL; Pérez González R
Med Clin (Barc); 2016 Jul; 147(2):56-62. PubMed ID: 27209224
[TBL] [Abstract][Full Text] [Related]
14. Functional role of endothelial CXCL16/CXCR6-platelet-leucocyte axis in angiotensin II-associated metabolic disorders.
Collado A; Marques P; Escudero P; Rius C; Domingo E; Martinez-Hervás S; Real JT; Ascaso JF; Piqueras L; Sanz MJ
Cardiovasc Res; 2018 Nov; 114(13):1764-1775. PubMed ID: 29800106
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
16. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
17. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.
Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
Clin Rheumatol; 2010 Oct; 29(10):1155-61. PubMed ID: 20690034
[TBL] [Abstract][Full Text] [Related]
18. CXCL16/CXCR6 Axis in Adipocytes Differentiated from Human Adipose Derived Mesenchymal Stem Cells Regulates Macrophage Polarization.
Lee SC; Lee YJ; Choi I; Kim M; Sung JS
Cells; 2021 Dec; 10(12):. PubMed ID: 34943917
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Miller RE; Branstetter D; Armstrong A; Kennedy B; Jones J; Cowan L; Bussiere J; Dougall WC
J Immunol; 2007 Jul; 179(1):266-74. PubMed ID: 17579046
[TBL] [Abstract][Full Text] [Related]
20. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
